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The challenge for Translational Pharmacology is to improve the predictive value of the tools that
are used to qualify the efficacy of a drug candidate. We should briefly consider the range of these
tools and provide conjecture as to where the limitations may be and how these may be addressed.
As this section of Frontiers develops, we will specifically welcome manuscripts that address ways of
improving drug candidate qualification.
There is a crisis in science that extends to medical science and to translational pharmacology.
The best publicized aspect of this complex crisis is in the widely acknowledged lack of
reproducibility of research findings (Baker, 2016). Several authors have written about specific
systematic attempts by Pharma (e.g., Amgen) to reproduce preclinical findings, with very low
success rates being reported (Begley and Ellis, 2012). These failures are attributed to a variety
of factors, including poorly specified methods, variable context-dependent behavior of tools and
cell lines, inadequate experimental power, post hoc analyses, and other forms of significance
finding (now commonly known as P hacking; Begley, 2013). The research community, including
the editorial board of the Frontiers series, is actively addressing the concerns raised by these
observations and the ensuing debate. More recently a damning view of clinical research as a whole,
has highlighted that many studies are redundant or non-feasible, creating waste, and unnecessary
risk to patients/volunteers (Ioannidis, 2016).
Closer to home we have some challenging failures in translational pharmacology. There have
been several systematic analyses of the causes of major pharma pipeline attrition up to phase
2 of development. These studies consistently identify lack of efficacy as the cause of failure in
approximately 50% of drug candidates (Cook et al., 2014). In this case, a “failure to fail” can
be identified. Where can improvements in the process be found that will reduce the number
of inefficacious candidates moving through to the later stages of clinical investigation? We have
written an extensive commentary on one aspect of the drug candidate qualification process, namely
the importance of cellular mechanics. We introduced the term “mechanopharmacology” to deal
not only with the effects of drugs on mechanics, but also the effects of mechanics on drug actions
(Krishnan et al., 2016), recognizing that the mechanical environment of the cells used in preclinical
cellular pharmacology studies is often non-(patho)physiological. At a molecular level, the term also
has utility in describing the impact of shear on molecular binding events and on protein shape.
The standard genomic-era processes often provide a target that has been identified through
analyses of differentially expressed mRNA transcripts and somewhat less commonly via
proteomics, particularly 2D differential in gel electrophoresis (2D-DIGE). The process of drug
target validation would typically include the use of a gene-edited cell line or transient interference
with siRNA to reduce protein expression, with phenotypic output of the assay system being assessed
in the context of stimulating or inhibiting the function of the target protein. In the absence of any
small molecule ligands, and presuming the target is intracellular and therefore not amenable to
targeting by biologicals, a high throughput screen is the likely next step. However, if the target
were in an accessible extracellular compartment then a biological approach may be as likely as a
small molecule screening campaign. The assessment of efficacy is likely to be addressed in animal
models and in a range of species, albeit that murine models are much more likely to be used than
others.When considering the likely sources of discordance that lead to failures in efficacy in phase 2
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clinical trials, the reliance on murine models looms large. There
are a number of considerations. Is the pathology of the targeted
condition faithfully reproduced? Has the model generated the
“right outcome” but for different reasons than the human
pathology it is intended to model. Is the model “too pure” in its
construction. That is to say, are there natural exposures in the
target human population that are not represented in the animal
facility, which is environmentally controlled with SPF status that
will influence the microbiome, an increasingly well-recognized
influence on each of the major chronic diseases, including allergy
(Marsland and Salami, 2015). Another feature of chronic diseases
is the existence of co-morbidities that are related to the primary
condition. However, often the animal model does not have a
duration that allows these to be expressed. Indeed, many of the
highest burden chronic diseases are associated with aging, or
have more significant impact in aged patients, but it is usually
prohibitively expensive to model the condition in aged mice.
Is there a solution for these widely acknowledged limitations
in the processes that are used to qualify drug candidates? The
recognition of these limitations is a useful starting point. Active
consideration of the role that aging, infection/microbiome, co-
morbid conditions, or the temporal development of chronic
disease and genetic/epi-genetic background brings into focus
possible strategies for risk mitigation. Thus, in my area of
greatest interest in the lung, a disease such as COPD presents
some significant challenges. The absence of any agents that
affect the natural history of the disease (asides from smoking
cessation adjunct therapies) attests to the difficulties. COPD
is a disease associated with aging which typically develops
after age 40, usually in individuals with a significant smoking
history and then continues to progress after cessation of smoke
exposure. Models in mice therefore are typically protracted
(months) to achieve similar emphysematous changes to those
in COPD patients, but I am not aware of any investigators that
have been able to demonstrate a model that shows progressive
lung function decline after smoking cessation. Evaluating drugs
during the smoking phase therefore limits the breadth of
potential applicability.
Thus, the grand challenge is to tackle the “failure to fail”
by identifying strategies that have higher predictive value,
but to do so in a cost and time effective manner. We think
that some of the answers will come from the burgeoning area
of cell/tissue/organ/disease-on-a-chip (Huh et al., 2013), as
such models may be configured to use cells from affected
patients of the right age and exposure history, obviating
some of the more striking limitations of mouse models
(Ingber, 2016). However, this technology is in its infancy,
has limited benchmarking and has its own limitations in
terms of a relative lack of cellular complexity and the usual
criticisms of cell/organoid culture around dimensionality
(2D vs. 3D), anatomical relationships and the deficiencies
in the physiological integration due to the absence of
neuroendocrine pathways. These challenges are being met
by spectacular advances in disease-on-a-chip technology,
promising improvements in lead qualification processes
across the spectrum of safety, efficacy, and pharmacokinetic
features that underwrite success in clinical progression of drug
candidates.
The Translational Pharmacology section looks forward to
receiving manuscripts that deal with drug target validation,
structure-activity relationships, bioassay, and animal model
development, with an emphasis on organ/disease-on-a-chip
technology; biomarker discovery, definition and validation;
pharmacodynamic/pharmacokinetic relationships; risk
mitigation approaches in the discovery/preclinical interface, and
other issues of relevance to the translational pathway.
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